Study Summary
The goal of this clinical study is to learn more about KTE-X19, and how safe and effective it is in adult Japanese participants with relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) or r/r B-precursor Acute Lymphoblastic Leukemia (B-ALL). The primary objectives of this study are to evaluate the efficacy of KTE-X19, as measured by: * Objective response rate (ORR) per investigator assessment, in adult Japanese participants with r/r MCL * Overall complete remission (OCR) defined as complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per investigator assessment, in adult Japanese participants with r/r ALL
Want to learn more about this trial?
Request More InfoInterventions
KTE-X19DRUG
A single infusion of chimeric antigen receptor (CAR) T cells
CyclophosphamideDRUG
Administered intravenously
FludarabineDRUG
Administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chiba University Hospital | Chiba | Japan | |
| Kyushu University Hospital | Fukuoka | Japan | |
| Hokkaido University Hospital | Hokkaido | Japan | |
| Kyoto University Hospital | Kyoto | Japan | |
| Tohoku University Hospital | Miyagi | Japan | |
| Okayama University Hospital | Okayama | Japan | |
| National Cancer Center Hospital | Tokyo | Japan | |
| Juntendo University Hospital | Tokyo | Japan | |
| Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital | Tokyo | Japan |